Rule2021-19220
Revision to Restrictions on Shipment or Use for Human Blood and Blood Components Exceptions; Technical Amendment
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 7, 2021
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or we) is amending the biologics regulation to improve clarity and revise an incorrect citation. This action is being taken to ensure the accuracy and clarity of the biologics regulation.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 170 (Tuesday, September 7, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 170 (Tuesday, September 7, 2021)]
[Rules and Regulations]
[Page 49922]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-19220]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 610
[Docket No. FDA-2021-N-0011]
Revision to Restrictions on Shipment or Use for Human Blood and
Blood Components Exceptions; Technical Amendment
AGENCY: Food and Drug Administration, Department of Health and Human
Services (HHS).
ACTION: Final rule; technical amendment.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is amending the
biologics regulation to improve clarity and revise an incorrect
citation. This action is being taken to ensure the accuracy and clarity
of the biologics regulation.
DATES: This rule is September 7, 2021.
FOR FURTHER INFORMATION CONTACT: Myrna Hanna, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-
402-7911.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of May 22, 2015 (80 FR 29842), FDA
published a final rule entitled ``Requirements for Blood and Blood
Components Intended for Transfusion or for Further Manufacturing Use''
(May 2015 final rule). In the May 2015 final rule, FDA amended Sec.
610.40(h)(2)(vii) (21 CFR 610.40(h)(2)(vii)), which provides for
exceptions to the restrictions on shipment or use of human blood and
blood components. The May 2015 final rule included an incorrect
regulatory citation in this provision.
II. Description of the Technical Amendments
In Sec. 610.40(h)(2)(vii), as amended by the May 2015 final rule,
FDA inadvertently cited Sec. 640.65(a)(2)(ii). The reference to Sec.
640.65(a)(2)(ii) is an incorrect citation. Accordingly, FDA is removing
the reference to Sec. 640.65(a)(2)(ii). Additionally, to improve the
clarity of the regulation, we are also amending Sec. 610.40(h)(2)(vii)
to replace the reference to Sec. 640.65(b)(2)(i) through (iv) with a
reference to Sec. 640.65(b)(2)(ii) through (iv). This amendment aligns
with the preamble of the May 2015 final rule, which stated that FDA was
``removing [the citation to] Sec. 640.65(b)(2), and replacing it with
the more precise citation to Sec. 640.65(b)(2)(ii) through
(b)(2)(iv)'' (May 2015 final rule, 80 FR 29842 at 29886). FDA notes
that donor protein composition assessment under Sec. 640.65(b)(2)(i)
is required for plasmapheresis procedures irrespective of whether or
not the syphilis screening requirements under Sec. 640.65(b)(2)(ii)
through (iv) are applicable.
III. Notice and Public Comment
Publication of this document constitutes final action of these
changes under the Administrative Procedure Act (5 U.S.C. 553). FDA has
determined that this rulemaking meets the notice and comment exemption
requirements in 5 U.S.C. 553(b)(3)(A) and (B). FDA has determined that
notice and public comment are unnecessary because the amendments to the
regulation provide only technical changes and are nonsubstantive.
List of Subjects in 21 CFR Part 610
Biologics, Labeling, Reporting and recordkeeping requirements.
Therefore, under the Federal Food, Drug, and Cosmetic Act, 21 CFR
part 610 is amended as follows:
PART 610--GENERAL BIOLOGICAL PRODUCTS STANDARDS
0
1. The authority citation for part 610 continues to read as follows:
Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 360, 360c,
360d, 360h, 360i, 371, 372, 374, 381; 42 U.S.C. 216, 262, 263, 263a,
264.
0
2. In Sec. 610.40, revise paragraph (h)(2)(vii) to read as follows:
Sec. 610.40 Test requirements.
* * * * *
(h) * * *
(2) * * *
(vii) You may use Source Plasma from a donor who tests reactive by
a screening test for syphilis as required under Sec. 640.65(b)(1)(i)
of this chapter, if the donor meets the requirements of Sec.
640.65(b)(2)(ii) through (iv) of this chapter.
Dated: August 31, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-19220 Filed 9-3-21; 8:45 am]
BILLING CODE 4164-01-P
</pre></body>
</html>Indexed from Federal Register on September 7, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.